BCIQ Profiles

Company Profile Report
DIST_0517_s43018-021-00208-6

Combining ULK1, ULK2 inhibition with anti-PD-1 therapy in NSCLC  

Jun 4, 2021 | 10:55 PM GMT

Read the full 146 word article

How to gain access

Continue reading with a
two-week free trial.